News

Kriya Therapeutics Welcomes Dr. Greg Di Russo as CMO

Kriya Therapeutics Welcomes Dr. Greg Di Russo as CMO

Kriya Therapeutics Names Dr. Greg Di Russo as Chief Medical Officer

Kriya Therapeutics, Inc., a key player in the clinical-stage biopharmaceutical arena, recently announced the appointment of Greg Di Russo, MD, as its new Chief Medical Officer. Dr. Di Russo will drive the company's medical operations and clinical strategy as Kriya continues to push innovative gene therapies forward.

Leadership Transition at Kriya

The leadership change comes at a pivotal moment for Kriya, which is dedicated to developing life-altering gene therapies aimed at conditions that impact millions globally. Dr. Shankar Ramaswamy, Co-Founder and CEO of Kriya, expressed enthusiasm regarding Dr. Di Russo's extensive experience. He stated, "Greg is a phenomenal leader with a track record of successfully developing complex products across diverse therapeutic areas. We look forward to his leadership as we scale the organization to tackle multiple chronic diseases of high unmet need and advance our mission of making gene therapy a cornerstone of mainstream medicine."

Dr. Di Russo's Background and Experience

Dr. Di Russo comes to Kriya with over two decades of diverse experience in clinical practice and the pharmaceutical industry. He has been involved in the development of various gene therapy and biologic products, gaining invaluable expertise in managing clinical trials and drug safety protocols. This rich background in both adult and pediatric medicine positions him as a strategic leader for overseeing Kriya's medical organization.

Insights on the Potential of Gene Therapy

Expressing his excitement about joining Kriya, Dr. Di Russo remarked, "I am delighted to be joining Kriya at this time, when advances in gene therapy have the potential to deliver transformative treatments to broad populations of patients with serious diseases. Kriya has the potential to leverage state-of-the-art science and technology to realize this potential with a collaborative, patient-centric approach." This focus on innovation and patient care is central to Kriya’s mission.

Key Achievements at Pfizer and Other Contributions

Prior to his role at Kriya, Dr. Di Russo served as the Development Head for Non-Malignant Hematology at Pfizer. In this capacity, he significantly contributed to the development of treatments for hemophilia and sickle cell disease, managing the gene therapies BEQVEZ™ and giroctocogene fitelparvovec, among other projects. His experience extends to notable roles at CSL Behring and Bristol-Meyers Squibb, where he helped advance therapeutic solutions.

Educational Background

Dr. Di Russo earned his medical degree from Sidney Kimmel Medical College, complemented by an undergraduate degree from Princeton University. His education and professional experience reflect a strong commitment to advancing healthcare.

About Kriya Therapeutics

Kriya Therapeutics operates with a clear mission: to revolutionize medicine and alleviate human suffering through advanced therapeutics. The company is committed to developing gene therapies targeting chronic diseases that affect populations around the world. Kriya boasts a robust pipeline of transformational medicines across various therapeutic areas, including ophthalmology, metabolic diseases, and neurology, underpinned by a proprietary manufacturing and engineering platform.

For more details about Kriya's initiatives and corporate philosophy, you can visit their official website and connect on LinkedIn and Twitter to stay updated on their progress.

Frequently Asked Questions

Who is the new Chief Medical Officer of Kriya Therapeutics?

Greg Di Russo, MD, has been appointed as the Chief Medical Officer of Kriya Therapeutics.

What is Dr. Di Russo's previous experience?

Dr. Di Russo previously served at Pfizer as the Development Head for Non-Malignant Hematology and has significant experience in gene therapy development.

What is the mission of Kriya Therapeutics?

Kriya Therapeutics aims to revolutionize medicine and eliminate human suffering through innovative gene therapies.

What areas does Kriya's pipeline target?

Kriya's pipeline includes therapies in ophthalmology, metabolic diseases, and neurology.

How can I stay updated on Kriya's developments?

You can follow Kriya Therapeutics on their official website, LinkedIn, and Twitter for the latest news and updates.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 92

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
Arbor Realty's Loan Mess Meets a Dividend Shutdown

Updated Category News Views 89

A dividend suspension lands differently when the loan book is already coughing up smoke. Arbor Realty Trust’s latest disclosed numbers are not the sort that investors can shrug off as one ugly quarter and forget by Friday. The company reported a third-quarter 2026 GAAP net loss of $85.4 million, suspended its quarterly cash dividend effective immediately, and described...

Continue Reading
Banks Face a Choice: Retreat or Fund Climate Resilience

Updated Category News Views 93

A flooded field can turn a prudent loan book into a social retreat overnight. That is the uncomfortable nerve in the Global Alliance for Banking on Values paper unveiled at COP31 in Antalya on November 19, 2026. Banks have become very practiced at mapping physical climate exposure, raising prices, tightening standards and stepping away. Fine, risk discipline matters. But...

Continue Reading
Harbour BioMed's LET003 Gets China's IND Green Light

Updated Category News Views 84

Muscle loss has become the awkward fact sitting beside every blockbuster obesity headline. Harbour BioMed's Nov. 18 announcement that China's National Medical Products Administration accepted its IND application for LET003 matters because the company is aiming directly at that problem: losing fat without giving away too much lean mass along the way. Acceptance Opens a...

Continue Reading
Kuaishou’s AI Push Meets a Brutal Earnings Reality

Updated Category News Views 91

Kuaishou just put a very expensive wrinkle in its AI story. The third-quarter figures are not a minor wobble: revenue dropped 11.1% year over year to RMB31.6 billion, gross margin slid from 54.7% to 48.2%, and the company swung from a RMB4.5 billion profit to a RMB959 million loss. For holders of 01024, that is the sort of earnings release that demands less daydreaming...

Continue Reading
FAMID's Six-Month IVDR Win Opens Europe's Market Door

Updated Category News Views 75

A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....

Continue Reading
Northstar's December Test: Metrics Over More Promises

Updated Category News Views 11

A shingle recycler earns its stripes when the machinery behaves, not when the slide deck does. Northstar Clean Technologies is putting Empower Calgary under a brighter light on December 1, pairing its third-quarter 2026 results with a comprehensive production update and a new set of operating metrics. For shareholders, especially those following OTCQB:ROOOF, this is the...

Continue Reading
T. Rowe Price Expands Teams Across 12 Fund Strategies

Updated Category News Views 35

A Quiet Personnel Shift With Real Stakes Twelve strategy changes may sound like administrative wallpaper, but asset managers live and die by who makes the calls. T. Rowe Price is broadening portfolio-management teams across equity and fixed-income offerings while insisting that each strategy's philosophy, process, and risk limits remain intact. Fine. That is the stated...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 82

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 72

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Unite: Taking Action Against aTyr Pharma's Misconduct

Updated Category News Views 142

Understanding the Case Against aTyr Pharma, Inc. Many investors have faced uncertainty in recent years, particularly in the healthcare sector. aTyr Pharma, Inc. (NASDAQ: ATYR) finds itself at the center of a securities fraud lawsuit, directed by the Schall Law Firm, designed to or encourage investors who may have been adversely impacted by the company's actions to take a...

Continue Reading
BIC Announces Rob Versloot as New CEO for Future Growth

Updated Category News Views 1055

Exciting Leadership Transition at BIC BIC has recently made a significant leadership transition by appointing Rob Versloot as the new Chief Executive Officer. This shift follows an extensive selection process conducted with utmost diligence and care by the Succession Committee under the guidance of Edouard Bich, the Chair of the Board of Directors. Background on Rob...

Continue Reading
Canadian Market Sees Gains as S&P/TSX Composite Hits Records

Updated Category News Views 167

Overview of the Canadian Stock Market Recently, the Canadian stock market has shown significant progress, culminating in a positive trading session that reflected growing investor confidence. The S&P/TSX Composite Index closed the day up by 0.40%, showcasing lively market activity and enthusiasm across various sectors. Sector Performances Fueling Market Gains Key sectors...

Continue Reading
Three Risky Consumer Staples That Might Struggle Soon

Updated Category News Views 153

Overview of Consumer Staples at Risk As recent market analysis highlights, several stocks in the consumer staples sector may be indicating potential challenges that investors should take into account. While consumer staples are generally viewed as safer investments, certain indicators suggest that this perception may not hold for every stock, especially in the current...

Continue Reading
Healthcare IT Outsourcing Market Projected to Reach $122.72 Billion

Updated Category News Views 156

Understanding the Surge in Healthcare IT Outsourcing The Healthcare IT Outsourcing Market signifies a booming ecosystem, anticipated to reach USD 122.72 billion by 2032, with a notable compound annual growth rate (CAGR) of 7.44%. The driving forces behind this remarkable growth are rooted in digital transformation and an increasing demand for operational efficiency....

Continue Reading